| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 15,836 | 9,944 |
| Net change in cash, cash equivalents and restricted cash | -244,847 | -220,476 |
| Effect of exchange rate changes on cash | 12,819 | - |
| Cash and cash equivalents at beginning of period | 771,743 | - |
| Cash and cash equivalents at end of period | 539,715 | - |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)